SCHEMBL24844006

SCHEMBL24844006

CC(C)C1CCCNCC1C(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.35
SLC6A11 P48066 1/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC6A13 Q9NSD5 1/20 0.35
APLNR P35414 2/20 0.34
GBA1 P04062 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
NOS2 P35228 1/20 0.34
CYP2D6 P10635 1/20 0.34
CPN1 P15169 1/20 0.32
CPB2 Q96IY4 1/20 0.32
TRPA1 O75762 2/20 0.31
TRPM8 Q7Z2W7 2/20 0.31
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22663314 0.93 GBA1 (0.33) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL10129888 0.85 KCNH2 (0.33) GBA1
SCHEMBL22663315 0.83 TRPA1 (0.32) SMN1; SMN2TRPA1TRPM8
SCHEMBL29299542 0.82 SLC6A1 (0.33) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL788564 0.76 GBA1 (0.44) GBA1KMT2A
SCHEMBL26452946 0.76 GBA1 (0.44) GBA1KMT2A
SCHEMBL29318345 0.74 GBA1 (0.42) GBA1TRPA1TRPM8
SCHEMBL29318343 0.74 GBA1 (0.42) GBA1TRPA1TRPM8
SCHEMBL7227000 0.74 GBA1 (0.42) GBA1TRPA1TRPM8
SCHEMBL10281960 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 SLC6A1 3079/4885SLC6A11 3477/4885TSHR 3593/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 SLC6A1 3079/4885SLC6A11 3477/4885TSHR 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.